Decitabine

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

サイズ 価格(税別)  
JPY 25730.00
JPY 14940.00
JPY 28220.00
JPY 53120.00
JPY 94620.00

カスタマーフィードバック(3)

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MYrGeY5kfGmxbjDBd5NigQ>? NWG4RnFMOC53wrFOwG0> NFWwZ40zPCCq M3LFRZdifGW{ MWHtc4R2dGG2ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCPQVfFMWEhdWWvYnXydy=> NH;KSVczPTF{M{C4Ni=>
Eca109 M{nYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH4dZJSOC53L{KuOU82KM7:TR?= MYmyOE81QC95MjDo NIrMfI14[XSnch?= MlmxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= NUizb2hbOjVzMkOwPFI>
Eca109 MYXGeY5kfGmxbjDBd5NigQ>? M4LS[|AvPcLizszN MnnpOk8yOi9{NDDo NXLocG1tf2G2ZYK= MWTpcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi M{C2XFI2OTJ|MEiy
Eca109 NVe3O4J[TnWwY4Tpc44hSXO|YYm= NH3LT3IxNjYEoN88US=> M2j5VFI1KGh? MWr3ZZRmeg>? MmDGbY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? NUjXSXdxOjVzMkOwPFI>
Eca109 MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PtOVAvPcLizszN MlexNlQhcA>? MlK5e4F1\XJ? NIDJ[YhqdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm NGTUO44zPTF{M{C4Ni=>
Eca109 NEe5fINHfW6ldHnvckBCe3OjeR?= NX;LdVVbOC53L{Gg{txO MWSyOEBp M1jZWJdifGW{ MmXM[IVkemWjc3XzJIV5eHKnc4Ppc44hd2ZiTl[t{tpDOiCjbnSgUW1ROg>? NXHIWHN7OjVzMkOwPFI>
SW1116  NHy5eINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWewMlUwOS9{L{Wg{txO Mn;3OFghcA>? NWTqXFJ2TE2VTx?= M1X1VoVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> NHjNb4gzPDh5NEK4Oi=>
LOVO M{TL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TXWlAvPS9zL{KvOUDPxE1? MljFOFghcA>? MlrBSG1UVw>? NF24UGNmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v M2HoflI1QDd2Mki2
SW1116  NGTVSFhHfW6ldHnvckBCe3OjeR?= MYSxNEDPxE1? NWDyUlV7PDhiaB?= NFj6RWlFVVOR Mm\UbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MVyyOFg4PDJ6Nh?=
LOVO NFzTeZpHfW6ldHnvckBCe3OjeR?= MmXRNVAh|ryP MVW0PEBp Mnq4SG1UVw>? MmP3bY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj Mk\rNlQ5PzR{OE[=
SW1116  NGe2NVZCeG:ydH;zbZMhSXO|YYm= MVixNEDPxE1? M{\OWlQ5KGh? MWDEUXNQ MmO2[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MVSyOFg4PDJ6Nh?=
LOVO M3znNmFxd3C2b4Ppd{BCe3OjeR?= NEnxNFAyOCEQvF2= NUD2VVl4PDhiaB?= MonOSG1UVw>? MYflcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= MnexNlQ5PzR{OE[=
RPMI-8226 NUDMO5ZoSXCxcITvd4l{KEG|c3H5 NF\HfGUyNzJizszN MlmwOFgwPzJxOU[gbC=> M1\DNWROW09? MWjpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MYWyOFg{OzFyOB?=
OPM-2  MoL0RZBweHSxc3nzJGF{e2G7 MW[xM|Ih|ryP M3\zT|czNzl4L{GyNEBp MXjEUXNQ MlrtbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NELwXFAzPDh|M{GwPC=>
JJN3  NH\r[pJCeG:ydH;zbZMhSXO|YYm= Mn\oNE42NzFizszN M4TzW|I1NzR6IHi= MYPEUXNQ MWXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ Mnj1NlQ5OzNzMEi=
NCI-H929  MkXtRZBweHSxc3nzJGF{e2G7 M2jWXFEwOiEQvF2= MkfJO|IwQTZxMUKwJIg> NETwU5lFVVOR M4G4dolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MVuyOFg{OzFyOB?=
RPMI-8226 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL6cFlLOS9{IN88US=> NEHt[XkzPC92OD:3NkBp MUnEUXNQ M{TxN4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NH7TN3UzPDh|M{GwPC=>
OPM-2  M1HRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rOVVEwOiEQvF2= MlvqNlQwPDhxN{KgbC=> NH\yZlJFVVOR NHHxeVBi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NF\Oc|gzPDh|M{GwPC=>
JJN3  NFLaNGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknhNE42NzFizszN NX60[FN4OjRxNEivO|IhcA>? MnrvSG1UVw>? NWLuOnhL[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MoHtNlQ5OzNzMEi=
NCI-H929  NUj0WWl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj3Tpk4OS9{IN88US=> NF:1cmIzPC92OD:3NkBp M1LWUWROW09? Mkm0ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MlOxNlQ5OzNzMEi=
HeLa MkjkT4lv[XOnIFHzd4F6 NGCySnBMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy NFjYNHkzPDd6MEC5PC=>
HeLa MWHLbY5ie2ViQYPzZZk> NXnsdGc4U2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz NEixfo4zPDd6MEC5PC=>
HeLa NGHVOohMcW6jc3WgRZN{[Xl? MnLYT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> NXHqTolUOjR5OECwPVg>
HeLa M37CO2tqdmG|ZTDBd5NigQ>? M3\nZ2tqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> M1naRVI1PzhyMEm4
NB4 M4jmOGZ2dmO2aX;uJGF{e2G7 NEnxcmQzNjVxNT:3MlUwOTBizszN M3O3cVI1KGh? MWLEUXNQ M{nyfIlv[3KnYYPlZUB1cGViZYjwdoV{e2mxbjDv[kBxemWldYLzc5IhdWmULUGyOYE> MnLMNlQ1QDR6N{C=
CD4+ CD25− T  NVWxcHBpTnWwY4Tpc44hSXO|YYm= MnvrNU82KM7:TR?= NUHZZYRPemWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w MXuyOFQ4PjN4MB?=
BV-173 NXPzXHBWSXCxcITvd4l{KEG|c3H5 NVXMW5VKOC5{NT:wMlUwOC55NT:xJO69VQ>? M{DKSFQ5Nzd{L{m2JIg> MXVCpHBDWw>? NFrXRlhqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NFzReo8zPDR{M{[xNy=>
ML-1 NEn0fGNCeG:ydH;zbZMhSXO|YYm= M4HmV|AvOjVxMD61M|AvPzVxMTFOwG0> M4j0fVQ5Nzd{L{m2JIg> MXlCpHBDWw>? MlXRbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MXOyOFQzOzZzMx?=
HL-60 NIjGOWdCeG:ydH;zbZMhSXO|YYm= MUKwMlI2NzBwNT:wMlc2NzFizszN NWjabFVzPDhxN{KvPVYhcA>? MlzvxsBRSlN? MnHibY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MlW0NlQ1OjN4MUO=
KG-1a NGn3UJZCeG:ydH;zbZMhSXO|YYm= NFXaUHMxNjJ3L{CuOU8xNjd3L{Gg{txO M3[xS|Q5Nzd{L{m2JIg> NH62S4HDqFCEUx?= NIH1elVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NUflb3YzOjR2MkO2NVM>
BV-173 M1TUOWZ2dmO2aX;uJGF{e2G7 NXzFb5BuOjVyL{WwNI5O NHrHVnI1QCCq MXtCpHBDWw>? NWjJNGRScW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl M1\sRVI1PDJ|NkGz
CEM MnP3SpVv[3Srb36gRZN{[Xl? MYOyOVAwPTBybl2= MlvnOFghcA>? MlPXxsBRSlN? MU\pcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NUDWWJBYOjR2MkO2NVM>
HL-60 MkPaSpVv[3Srb36gRZN{[Xl? NXG0OnVEOjVyL{WwNI5O NGrIXI01QCCq M1zvUuKhWEKV MYPpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NIXScVYzPDR{M{[xNy=>
ML-1 MWrGeY5kfGmxbjDBd5NigQ>? MXmyOVAwPTBybl2= MoWxOFghcA>? NIP3Zm7DqFCEUx?= MW\pcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NYXYSGFHOjR2MkO2NVM>
DLD-1 MoK3SpVv[3Srb36gRZN{[Xl? M2e1NlI2OC93MEDuUS=> MUe0PEBp NWfM[2dlyqCSQmO= Mk\w[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? MojkNlQ1OjN4MUO=
HCT-116 NGG3N|NHfW6ldHnvckBCe3OjeR?= NEm5fXozPTBxNUCwcm0> NUXRTWN7PDhiaB?= MVRCpHBDWw>? NGDWZVhldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M1\lOlI1PDJ|NkGz
U937-A/E-9/14/18  Ml3sRZBweHSxc3nzJGF{e2G7 MX[wMlAyNzBwMT:xM|ExKM7:TR?= NVXxNGhCPDhiaB?= MYDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2ewN|I1OzByNEW2
HT29 NV63XYI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe3NkBp M3m2V2lEPTB;MUSwNOKyOTd7IN88US=> M4H0UFI1OTd{ME[x
SW48 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LVflczKGh? Mn7OTWM2OD1zNT6yxtE3NjJizszN MUKyOFE4OjB4MR?=
HCT116 M1zoZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG2TGY4OiCq MkfnTWM2OD1zLkhCtVAvPCEQvF2= MUWyOFE4OjB4MR?=
HepG2 MVjGeY5kfGmxbjDBd5NigQ>? MUewMlUwOSEQvF2= NVnW[ZJLOjRiaB?= M2fJUmROW09? NHyxRpp2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MYGyOFE1Pjh5NB?=
LS174T MnfESpVv[3Srb36gRZN{[Xl? M1nXUlAvPS9zIN88US=> NEHGRW0zPCCq M3yxemROW09? M{LQNIxm[WRidH:gZY4hcW6lcnXhd4Uhd2ZiT1PUUlIhdGW4ZXzz M{i4ZlI1OTR4OEe0
HepG2 MlzSRZBweHSxc3nzJGF{e2G7 MYCxM|ExNzFyMDFOwG0> NIXSbVY4KGR? NWi1VmJ5TE2VTx?= M2rNWolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MViyOFE1Pjh5NB?=
LS174T MoL6RZBweHSxc3nzJGF{e2G7 MYKxM|ExNzFyMDFOwG0> NXzoeII5PyCm MYjEUXNQ MknrbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NEPONJozPDF2Nki3OC=>
QBC-939 M2f0RmFxd3C2b4Ppd{BCe3OjeR?= M1iySFEwOTBxMUCwJO69VQ>? NVfUfppMPyCm MV7EUXNQ M{j3Nolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MU[yOFE1Pjh5NB?=
U251 MljVRZBweHSxc3nzJGF{e2G7 NHnvfmIyNzFyL{GwNEDPxE1? M4Cyb|ch\A>? MWLEUXNQ MYnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFzHb4MzPDF2Nki3OC=>
HL-60 NWPJd3dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnmTlEyKM7:TR?= MYO0PEBp MlnkbY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? MVKyOFAxODN{NB?=
MDA‑MB‑453 NYKy[ZB7TnWwY4Tpc44hSXO|YYm= NHfy[mgxNjJxMTFOwG0> M1rueVczKGh? M2PmTINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> M3nHO|I{QDR2MkK4
HCC1569 MmfBSpVv[3Srb36gRZN{[Xl? NX\PWGFVOC5{L{Gg{txO Ml:3O|IhcA>? MlrIZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg MVeyN|g1PDJ{OB?=
BT‑474 M4LZWGZ2dmO2aX;uJGF{e2G7 NVfOXXozOC5{L{Gg{txO M{S3TFczKGh? Mnz4Z4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg MWqyN|g1PDJ{OB?=
AGS NUD3[lh7SXCxcITvd4l{KEG|c3H5 NHXwZZA2NzFyL{KwM|UxKM7:TR?= NUHkOmNYPDkEoHlCpC=> Mk\qSG1UVw>? MmnBbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> NUX1dZU5OjN3OEK3PFQ>
A549 M3nqNGFxd3C2b4Ppd{BCe3OjeR?= MXO1M|ExNzJyL{WwJO69VQ>? NX7mU2g4PDkEoHlCpC=> NFfFWo9FVVOR M4i1RYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NHLWSIIzOzV6Mke4OC=>
AGS  Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXO1M|ExNzJyL{WwJO69VQ>? MUe0POKhcMLi MX7EUXNQ Mo\TbY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg NYPaT2xLOjN3OEK3PFQ>
Kasumi-1 MnOzRZBweHSxc3nzJGF{e2G7 NUfS[HE3OC53IN88US=> NYLkOoljPDkEoHlCpC=> MojV[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= M1XZXVI{PDl|M{S4
OCI-AML3 MoTTRZBweHSxc3nzJGF{e2G7 Mln0Nk42KM7:TR?= NX3H[lBTPDkEoHlCpC=> MXHk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= Mnq4NlM1QTN|NEi=
MV4-11 NWnRenRWSXCxcITvd4l{KEG|c3H5 NFHVU4QzNjVizszN M{TINFQ5yqCqwrC= Ml\r[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= M1L6elI{PDl|M{S4
NK  NWC4[m5RS3m2b4TvfIl1gSCDc4PhfS=> M3fGR|AvODJvMkCg{txO M3LsNlUh\A>? MkLa[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26|ZTDjeZJ3\Q>? NF;vd4EzOzN{OEC4PC=>
NK  NIjaWllCeG:ydH;zbZMhSXO|YYm= NXW3WZZPOC5yMj2yNEDPxE1? MUe1JIQ> Mn;I[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl M1HpTVI{OzJ6MEi4
NK  Mn7NSpVv[3Srb36gRZN{[Xl? MlvsNE4xOS1{MDFOwG0> M{P2VFUh\A>? NXXNcYZz[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>? NYjETpprOjN|MkiwPFg>
MOLT4/DNR M4jDN2Z2dmO2aX;uJGF{e2G7 NIjyRVM2KM7:TR?= MWG0JIQ> NVq0OHRxemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? M1\Ee|I{ODZyNUew
Jurkat/DOX MXnGeY5kfGmxbjDBd5NigQ>? MWG1JO69VQ>? NU\aOZZ5PCCm NGXn[GZz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? Mn3NNlMxPjB3N{C=
MOLT4/DNR NEfHcHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOxRlg5PSEQvF2= NGXSNW01KGR? MlrzdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= Ml;QNlMxPjB3N{C=
Jurkat/DOX MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\veVUh|ryP NEXyN4I1KGR? MlnBdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= MXOyN|A3ODV5MB?=
ccRCC  NHTENHNCeG:ydH;zbZMhSXO|YYm= MYqwMlAyNTFyzszN NXPxfFA5PzJiaB?= NEjGeFdFVVOR MWPoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NHvCXWIzOjh{NkS2Oy=>
TNBC  NEPmeZNCeG:ydH;zbZMhSXO|YYm= MVuwMlAyNTFyzszN NHThfGk4OiCq M1L0dmROW09? MXfoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NULtZWZ4OjJ6Mk[0Olc>
A498 MXPBdI9xfG:|aYOgRZN{[Xl? NXrLO2F7OC5yMT2xNO69VQ>? MkHGO|IhcA>? MYLEUXNQ NIjrc41qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MVKyNlgzPjR4Nx?=
KIJ265T M1;6SGFxd3C2b4Ppd{BCe3OjeR?= MVywMlAyNTFyzszN Ml;MO|IhcA>? NIHweXNFVVOR NXjUSZdicW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? M4HKZlIzQDJ4NE[3
MDA-231 MlT1RZBweHSxc3nzJGF{e2G7 NHjmS5gxNjBzLUGw{txO MUC3NkBp NFjHSXNFVVOR NHr5d5NqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NYXoenVqOjJ6Mk[0Olc>
BT-20 MmjmRZBweHSxc3nzJGF{e2G7 NVv4NpV4OC5yMT2xNO69VQ>? M133PFczKGh? M1TQRWROW09? Mln2bY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MkHaNlI5OjZ2Nke=
U937 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\YSZk2NTJyIN88US=> MWOyOE81QC95MjDo MV;pcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M3LJRlIzPzZ5MEKx
HL60 NGXiPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXu1MVIxKM7:TR?= MU[yOE81QC95MjDo NX;jd41icW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MmDINlI4PjdyMkG=
U937 M2G0VGFxd3C2b4Ppd{BCe3OjeR?= MnWwNVUh|ryP NX7ES5ZUOjRxNEivO|IhcA>? MWXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M1rNO|IzPzZ5MEKx
HL60 Mnm1RZBweHSxc3nzJGF{e2G7 MkCzNVUh|ryP MViyOE81QC95MjDo NYDRXZBjcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHjmZpUzOjd4N{CyNS=>
LS411N  MVvBdI9xfG:|aYOgRZN{[Xl? MXGwMlUh|ryP MnfWO|IhcA>? M{nrPYlv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= NUjBdWxzOjJ2NkG2PVU>
MDA-MB-231 MmrYRZBweHSxc3nzJGF{e2G7 MoXPNVAh|ryP NVnLfWhGPDhiaB?= NHLHcnNz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2fKOlIyQDh5Nkm3
MCF-7  MkTkRZBweHSxc3nzJGF{e2G7 NYnQUIR1OTBizszN MYi0PEBp NW\id4NLemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MljPNlE5QDd4OUe=
A375 NF[y[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfmTFUxNjVizszN Mn65NU82NzhiZB?= MXzpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MVuyNVc6PjZ{Mh?=
SKMEL1 M1nOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnQbXAxNjVizszN NUXTdHhIOS93L{ig[C=> MV7pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MmD5NlE4QTZ4MkK=
SKMEL3 Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXwT|IxNjVizszN NHTST5IyNzVxODDk MnjFbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MWKyNVc6PjZ{Mh?=
SKMEL28 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\sNE42KM7:TR?= MmDENU82NzhiZB?= M2TZR4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NETrSoszOTd7Nk[yNi=>
MeWo MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqwMlUh|ryP NVjFWJc{OS93L{ig[C=> M4joR4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| Mo\oNlE4QTZ4MkK=
B16 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjINE42KM7:TR?= M2HRVFEwPS96IHS= NHexfpdqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M{jyRVIyPzl4NkKy
Ly 1 M{nW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PFTFI1KGh? NEGxb2dKSzVyPUeuN{DPxE1? MYGyNVc4OjB2OR?=
Ly 7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjlUmwzPCCq MnLiTWM2OD1zMD63JO69VQ>? MWeyNVc4OjB2OR?=
Su-DHL6 NWrEd2t[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[yOEBp M4DzbGlEPTExvK6yNEDPxE1? NYLmeYxGOjF5N{KwOFk>
Ly 10 NGWyOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXlWVEzPCCq MV;JR|Ux97zgMkCg{txO MmfwNlE4PzJyNEm=
RIVA M3ywZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTvNlQhcA>? NHvBb4tKSzVy78{eNlAh|ryP M2\jTVIyPzd{MES5
Su-DHL2 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL5NlQhcA>? NUDZWHUzUUN3MP-8olIxKM7:TR?= NUnxVGNSOjF5N{KwOFk>
Ly 1 NX2xRo9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHJOFghcA>? M1fRe2lEPTB;MD6zOEDPxE1? NWTz[JVtOjF5N{KwOFk>
Ly 7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETvXng1QCCq NIDXVYpKSzVyPUCuNFI2KM7:TR?= M4GyTFIyPzd{MES5
Su-DHL6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjMcYQ1QCCq NWjl[4x7UUN3MP-8olIxKM7:TR?= MlzsNlE4PzJyNEm=
Ly 10 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DpWVQ5KGh? MmTRTWM2OD1zLkig{txO MnewNlE4PzJyNEm=
RIVA M12x[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3O[HM1QCCq Mnn4TWM2OO,:nkKwJO69VQ>? M1TpRVIyPzd{MES5
Su-DHL2 M3GxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnvd2dDPDhiaB?= MUXJR|UxRTF5LkSg{txO M1LKdFIyPzd{MES5
Ly 1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPtV|hbPzJiaB?= Mne4TWM2OD1yLkCxJO69VQ>? MmrZNlE4PzJyNEm=
Ly 7 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[5Ooo4OiCq M4PBcmlEPTB;MD6wNVgh|ryP MlHWNlE4PzJyNEm=
Su-DHL6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm2RXc4OiCq MlviTWM2OD1zLk[g{txO M4ThR|IyPzd{MES5
Ly 10 NVfTTphuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj5fFNmPzJiaB?= Mn:xTWM2OD1zLkKg{txO NF\TR4EzOTd5MkC0PS=>
RIVA NH;iPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33hWlczKGh? M4DTRmlEPTExvK6yNEDPxE1? MoX2NlE4PzJyNEm=
Su-DHL2 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v2ZlczKGh? MnuyTWM2OD1zMT6yJO69VQ>? MkP1NlE4PzJyNEm=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID